| Nov 20 |
IceCure Medical to Report Third Quarter 2024 Financial & Operational Results on November 26, 2024
|
| Nov 19 |
IceCure's ProSense® Chosen for Breast Cryoablation Study Led by the Prestigious European Institute of Oncology with Sponsorship from the Italian Ministry of Health
|
| Nov 11 |
IceCure’s cryoablation system for breast cancer treatment gains FDA panel support
|
| Nov 8 |
IceCure gets favorable FDA AdCom vote for ProSense System
|
| Nov 8 |
FDA Advisory Panel Votes in Favor of IceCure's ProSense® Cryoablation Benefit-Risk Profile in Early-Stage Low Risk Breast Cancer
|
| Oct 29 |
Upcoming FDA Advisory Panel for IceCure's ProSense® Marketing Authorization Receives Large Number of Public Comments from Stakeholders
|
| Oct 21 |
IceCure Receives Notice of Allowance from U.S. Patent and Trademark Office for its Next-Generation Cryoablation System
|
| Oct 15 |
IceCure Medical files to sell ordinary shares and warrants
|
| Oct 10 |
Alignment HealthCare Partners With Intermountain Health in Nevada
|
| Oct 7 |
IceCure's ProSense® Featured in 6 Global Studies on Cryoablation of Breast Tumors at the 2024 European Society of Breast Imaging Conference
|
